Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.64 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.62 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1497335 | 1.00 | PIK3CA (0.64) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1497501 | 0.93 | PIK3CA (0.69) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1497498 | 0.93 | PIK3CA (0.69) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL2396645 | 0.88 | PIK3CA (0.68) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1497332 | 0.88 | PIK3CA (0.68) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1497315 | 0.86 | PIK3CA (0.67) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1497495 | 0.84 | PIK3CA (0.76) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1497496 | 0.84 | PIK3CA (0.76) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL12832388 | 0.83 | PIK3CA (0.75) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL964129 | 0.83 | PIK3CA (0.76) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230476-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | PIK3CA 1/4885PIK3CD 5/4885PIK3CB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.